Adv Ther (2017) 34:1791–1814 DOI 10.1007/s12325-017-0499-6 REVIEW A Review of the Long-Term Efﬁcacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes . . Stefano Genovese Edoardo Mannucci Antonio Ceriello Received: March 22, 2016 / Published online: July 3, 2017 The Author(s) 2017. This article is an open access publication insulin glargine, as measured by HbA1c. In ABSTRACT drug-naı¨ve patients ExeOW was superior to sitagliptin and non-inferior to metformin, Introduction: Exenatide once weekly (ExeOW, whereas non-inferiority to pioglitazone and Bydureon , Astra Zeneca), a drug belonging to liraglutide was not proven. In different trials the class of glucagon-like peptide-1 (GLP-1) reductions in HbA1c ranged from -1.1% to receptor agonists, is the ﬁrst agent approved for -2.0%. ExeOW therapy over 6 months was also treatment of type 2 diabetes (T2D) that can be associated with a mean weight loss of -2to administered on a weekly basis. -4 kg, improved systolic blood pressure and Methods: Data concerning treatment of T2D lipid proﬁle, and no hypoglycemia unless asso- with ExeOW are reviewed with special reference ciated to sulfonylurea. ExeOW long-term ther- to its long-term efﬁcacy, tolerability, and safety. apy up to 3–6 years allowed persistent glycemic Relevant literature was identiﬁed
Advances in Therapy – Springer Journals
Published: Jul 3, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera